Birchtech Posts 32% Revenue Growth to $4.2M, Raises $16.4M in NYSE Uplisting
Birchtech’s first-quarter revenues climbed 32% year-over-year to $4.2 million, narrowing its net loss to $1.3 million from $1.7 million while adjusted EBITDA loss improved to $1.0 million. The company raised $16.4 million through its NYSE American uplisting, launched SEA-IX™ resin line with $1 million in orders and is pursuing a $78 million judgment collection.
1. Financial Performance
Birchtech recorded first-quarter revenues of $4.2 million, up 32% year-over-year, driven by growth in its water treatment and air business lines. The company reduced its net loss to $1.3 million from $1.7 million a year earlier, while adjusted EBITDA loss improved to $1.0 million.
2. NYSE American Uplisting
In February 2026, Birchtech uplisted to the NYSE American and completed a public offering that raised $16.4 million in gross proceeds. The capital infusion increased cash to $14.7 million as of March 31, 2026, and left Birchtech with zero debt.
3. Product Launch and Judgment Collection
Birchtech launched its SEA-IX™ nuclear-grade ion exchange resin line, securing approximately $1 million in initial orders to tap into a $220 million addressable market spanning nuclear, utilities, and municipal water treatment. Concurrently, the company initiated collection efforts on a $78 million final patent infringement judgment, with post-judgment interest accruing while defendants pursue an appeal without posting a bond.
4. Leadership and Partnerships
The company strengthened its leadership with the appointment of Michael Mioska as CFO and expanded its Analytical Design Center in partnership with Civil & Environmental Consultants to offer RSSCT testing to water-utility clients nationwide. Birchtech also announced participation in four major water industry conferences through June 2026 to showcase its expanding water treatment solutions.